The estimated Net Worth of David M Reese is at least 20.4 百万$ dollars as of 16 February 2021. Mr. Reese owns over 2,300 units of AMGEN stock worth over 13,878,629$ and over the last 6 years he sold AMGN stock worth over 0$. In addition, he makes 6,537,920$ as Executive Vice President - Research and Development at AMGEN.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Reese AMGN stock SEC Form 4 insiders trading
David has made over 2 trades of the AMGEN stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,300 units of AMGN stock worth 125,787$ on 16 February 2021.
The largest trade he's ever made was exercising 2,300 units of AMGEN stock on 16 February 2021 worth over 125,787$. On average, David trades about 102 units every 9 days since 2018. As of 16 February 2021 he still owns at least 42,059 units of AMGEN stock.
You can see the complete history of Mr. Reese stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Reese biography
David M. Reese serves as Executive Vice President - Research and Development of the Company. Dr. Reese joined the Company in 2005 and has held leadership roles in development, medical sciences and discovery research. Dr. Reese was Senior Vice President, Translational Sciences and Oncology from 2017 to 2018 and Senior Vice President, Translational Sciences from 2015 to 2017. Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group from 2001 to 2003 and a cofounder, president and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, from 2003 to 2005. Dr. Reese previously served on the faculty at University of California, Los Angeles, and the University of California, San Francisco.
What is the salary of David Reese?
As the Executive Vice President - Research and Development of AMGEN, the total compensation of David Reese at AMGEN is 6,537,920$. There are 3 executives at AMGEN getting paid more, with Robert Bradway having the highest compensation of 19,612,800$.
How old is David Reese?
David Reese is 57, he's been the Executive Vice President - Research and Development of AMGEN since 2018. There are 17 older and 8 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
What's David Reese's mailing address?
David's mailing address filed with the SEC is 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.
Insiders trading at AMGEN
Over the last 22 years, insiders at AMGEN have traded over 219,663,137$ worth of AMGEN stock and bought 8,904 units worth 919,219$ . The most active insiders traders include Robert Eckert、Kevin W Sharer、Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of 8,732,261$. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth 662,812$.
What does AMGEN do?
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
What does AMGEN's logo look like?
Complete history of Mr. Reese stock trades at AMGEN
AMGEN executives and stock owners
AMGEN executives and other stock owners filed with the SEC include:
-
Robert Bradway,
Chairman of the Board, President, Chief Executive Officer -
Jonathan Graham,
Senior Vice President, General Counsel, Secretary -
Murdo Gordon,
Executive Vice President of Global Commercial Operations -
David Reese,
Executive Vice President - Research and Development -
Robert A. Bradway,
Chairman, CEO & Pres -
Murdo Gordon,
Exec. VP of Global Commercial Operations -
Dr. David M. Reese M.D.,
Exec. VP of R&D -
Esteban Santos,
Exec. VP of Operations -
Peter H. Griffith,
Exec. VP & CFO -
Robert Eckert,
Lead Independent Director -
Gregory Garland,
Independent Director -
Ronald Sugar,
Independent Director -
Charles Holley,
Independent Director -
Wanda Austin,
Independent Director -
Brian Druker,
Independent Director -
Fred Hassan,
Independent Director -
Robert Williams,
Independent Director -
Tyler Jacks,
Independent Director -
Ellen Kullman,
Independent Director -
Amy Miles,
Independent Director -
Linda Louie,
Vice President - Finance, Chief Accounting Officer -
David Piacquad,
Senior Vice President - Business Development -
Lori Johnston,
Senior Vice President - Human Resources -
Cynthia Patton,
Senior Vice President, Chief Compliance Officer -
Esteban Santos,
Executive Vice President, Operations -
Peter Griffith,
Chief Financial Officer, Executive Vice President -
Nancy A. Grygiel,
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer -
Jonathan P. Graham,
Exec. VP, Gen. Counsel & Sec. -
Arvind Sood,
VP of Investor Relations -
Mike Zahigian,
Sr. VP & Chief Information Officer -
Linda H. Louie,
VP of Fin. & Chief Accounting Officer -
Annette Louise Such,
CAO -
Frank Biondi,
Director -
Greg C. Garland,
Director -
Frank C Herringer,
Director -
David W Meline,
EVP & CFO -
Anthony C Hooper,
EVP, Global Commercial Ops. -
R Sanders Williams,
Director -
Rebecca M Henderson,
Director -
Judith C Pelham,
Director -
David Baltimore,
Director -
Sean E Harper,
EVP, Research & Development -
Carbonnel Francois De,
Director -
James E. Bradner,
EVP, R&D, & Chief Sci. Officer -
Nancy A. Grygiel,
SVP & CCO -
Thomas James Flanagan,
Sr VP & CIO -
Leonard D Schaeffer,
Director -
Jonathan M Peacock,
CFO -
Gilbert S Omenn,
Director -
J Paul Reason,
Director -
Thomas J.W. Dittrich,
VP, Finance & CAO -
David J Scott,
Sr. VP, Gen. Counsel & Secy. -
A Kelly Michael,
VP Corp Plng & Control & CAO -
Stuart A Tross,
SVP, Human Resources -
Kevin W Sharer,
Chairman of the Bd, CEO & Pres -
Vance D Coffman,
Director -
David W Beier,
SVP Global Govt & Corp Affairs -
Fabrizio Bonanni,
Senior VP, Manufacturing -
Anna Richo,
SVP & CCO -
Jerry D Choate,
Director -
Frederick W Gluck,
Director -
Roger M Perlmutter,
Exec VP Research & Development -
George J Morrow,
Exe VP, Global Commercial Ops -
Brian M Mcnamee,
Sr. V.P. Human Resources -
Richard D Nanula,
Exe VP Fin, Strat & Comm & CFO -
Franklin P Jr Johnson,
Director -
Donald B Rice,
Director -
Dennis M Fenton,
Executive Vice President -
Hassan Dayem,
Sr. V.P. & Chief Info. Officer -
Barry D Schehr,
VP Financial Ops & CAO -
Edward V Fritzky,
Director -
Steven M Odre,
Sr. VP, Gen. Cousel & Secy. -
Timothy O Martin,
V.P., Planning and Control -
Beth C Seidenberg,
Sr VP Development -
Willard H Dere,
Sr. V.P., Global Dev & CMO -
Joseph P Miletich,
Sr VP Rsch & Preclinical Dev -
Patricia C Sueltz,
Director -
Steven Lazarus,
Director -
Derek Miller,
SVP, Human Resources -
Omar Ishrak,
Director -
Rachna Khosla,
SVP, Business Development -
Michael V Drake,
Director -
Matthew C. Busch,
VP, Finance & CAO -
Mary E. Klotman,
Director